These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32229581)
1. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD). Harris KL; Kuan WL; Mason SL; Barker RA J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):622-630. PubMed ID: 32229581 [TBL] [Abstract][Full Text] [Related]
2. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Claassen DO; Philbin M; Carroll B Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641 [No Abstract] [Full Text] [Related]
3. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Verhagen Metman L; Morris MJ; Farmer C; Gillespie M; Mosby K; Wuu J; Chase TN Neurology; 2002 Sep; 59(5):694-9. PubMed ID: 12221159 [TBL] [Abstract][Full Text] [Related]
4. The Neuropsychiatry of Huntington Disease-Like 2: A Comparison with Huntington's Disease. Ferreira-Correia A; Krause A; Anderson DG J Huntingtons Dis; 2020; 9(4):325-334. PubMed ID: 33044188 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic approaches to the treatment of Huntington's disease. Venuto CS; McGarry A; Ma Q; Kieburtz K Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232 [TBL] [Abstract][Full Text] [Related]
6. [Olanzapine improves chorea in patients with Huntington's disease]. Jiménez-Jiménez FJ; de Toledo M; Puertas I; Barón M; Zurdo M; Barcenilla B Rev Neurol; 2002 Sep 16-30; 35(6):524-5. PubMed ID: 12389168 [TBL] [Abstract][Full Text] [Related]